US equities |
MU $1,041.15 ▼-4.31% NVDA $230.47 ▼-2.95% SNDK $1,610.04 ▼-4.87% AMD $618.33 ▼-4.26% INTC $106.00 ▼-6.30% SPCX $162.11 ▼-3.28% META $716.13 ▼-0.72% PLTR $196.28 ▲+1.11%
FinancialContent

Filana Therapeutics, Inc. - Common Stock (NQ:FLNA)

0.7949 -0.0208 (-2.55%)
Delayed Quote Updated: 1:52 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Filana Therapeutics, Inc. - Common Stock

These stocks are moving in today's after hours session ↗
Via Chartmill
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
Which stocks are most active on Tuesday? ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
From Filana Therapeutics, Inc.
Via GlobeNewswire
News headline image
Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
From Filana Therapeutics, Inc.
Via GlobeNewswire
News headline image
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
From Filana Therapeutics, Inc.
Via GlobeNewswire
News headline image
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
Presentation described the biological rationale for the evaluation of simufilam in TSC-related epilepsy 
From Filana Therapeutics, Inc.
Via GlobeNewswire
News headline image
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
From Filana Therapeutics, Inc.
Via GlobeNewswire
News headline image
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Working to advance TSC-related epilepsy program, with a focus on capital efficiency 
From Filana Therapeutics, Inc.
Via GlobeNewswire